Anaptysbio (ANAB) EBT (2016 - 2026)
Anaptysbio's (ANAB) quarterly EBT came in at -$52.8 million in Q1 2026, down 34.51% YoY from -$80.7 million in Q1 2025, and down 206.34% on a QoQ basis from $49.7 million in Q4 2025.
Anaptysbio (ANAB) EBT (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of EBT data on file, last reported at -$52.8 million in Q1 2026.
- Quarterly EBT fell 34.51% year-over-year to -$52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.6 million (up 81.06% YoY) and the FY2025 annual result came in at -$13.1 million, up 91.0% from the prior year.
- EBT declined to -$52.8 million in Q1 2026, from $49.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $49.7 million in Q4 2025 to a low of -$62.6 million in Q1 2023.
- A 5-year average of -$33.0 million and a median of -$39.3 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 94.94% — and 2025, when it soared 328.06%.
- Tracing ANAB's EBT over 5 years: stood at -$22.7 million in 2022, then sank by 85.63% to -$42.2 million in 2023, then jumped by 48.33% to -$21.8 million in 2024, then surged by 328.06% to $49.7 million in 2025, then slumped by 206.34% to -$52.8 million in 2026.
- The last three EBT figures came in at -$52.8 million (Q1 2026), $49.7 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -52.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.84 Mn |
| Dec 31, 2025 | 49.70 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.59 Mn |
| Mar 31, 2025 | -39.29 Mn |
| Dec 31, 2024 | -21.79 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.65 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -42.17 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -62.55 Mn |
| Dec 31, 2022 | -22.72 Mn |
| Sep 30, 2022 | -37.62 Mn |
| Jun 30, 2022 | -51.08 Mn |
| Mar 31, 2022 | -56.38 Mn |
| Dec 31, 2021 | -32.13 Mn |
| Sep 30, 2021 | -33.69 Mn |
| Jun 30, 2021 | -26.20 Mn |